The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
The transitional period before and after MENOPAUSE. Perimenopausal symptoms are associated with irregular MENSTRUAL CYCLE and widely fluctuated hormone levels. They may appear 6 years before menopause and subside 2 to 5 years after menopause.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
The premature cessation of menses (MENSTRUATION) when the last menstrual period occurs in a woman under the age of 40. It is due to the depletion of OVARIAN FOLLICLES. Premature MENOPAUSE can be caused by diseases; OVARIECTOMY; RADIATION; chemicals; and chromosomal abnormalities.
The concept covering the physical and mental conditions of women.
The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures.

Oxytocin and vasopressin receptors in human and uterine myomas during menstrual cycle and early pregnancy. (1/1495)

The purpose of this study was to determine the specificity and concentration of oxytocin (OT) and arginine vasopressin (AVP) binding sites in non-pregnant (NP) human and rhesus monkey endometrium, myometrium and fibromyomas, and to determine the cellular localization of OT receptor (OTR). Besides [3H]AVP, [125I]LVA, a specific VP1 receptor subtype antagonist, was used to determine vasopressin receptor (VPR) concentrations. Samples were obtained from 42 pre-menopausal and three pregnant women (5, 13 and 35 weeks gestation), and several NP and pregnant monkeys. Specificity of binding was assessed in competition experiments with unlabelled agonists and antagonists of known pharmacological potency. Cellular localization of OTR was determined by immunohistochemistry. In NP human uterine tissues, [3H]AVP was bound with higher affinity and greater binding capacity than [3H]OT, whereas in pregnant women and in NP and pregnant rhesus monkeys, uterine OT binding capacity was greater. OT and AVP binding sites discriminated very poorly between OT and AVP; [125I]LVA binding sites were more selective than [3H]AVP. Their ligand specificity and binding kinetics indicated the presence of two distinct populations of binding sites for OT and AVP in primate uterus. Endometrium of NP women and monkeys had low OTR and VPR concentrations. Myometrial and endometrial OTR and VPR were down-regulated in midcycle and in early human pregnancy, they were up-regulated in the secretory phase and second half of pregnancy. Immunoreactive OTR in NP uterus was localized in patches of myometrial muscle cells and small numbers of endometrial epithelial cells.  (+info)

Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. (2/1495)

Glutathione-S-transferases catalyze the detoxication of carcinogen metabolites and reactive oxygen species (ROS) produced through a number of mechanisms. Glutathione-S-transferase (GST) M1 is polymorphic, and the null allele results in a lack of enzyme activity. Because there are indications that ROS may be involved in breast carcinogenesis, we sought to determine whether the GSTM1 null allele was associated with increased breast cancer, particularly among women with lower consumption of dietary sources of alpha-tocopherol, carotenoids and ascorbic acid. In a study of diet and cancer in western New York, women with primary, incident, histologically confirmed breast cancer (n = 740) and community controls (n = 810) were interviewed and an extensive food-frequency questionnaire administered. A subset of these women provided a blood specimen. DNA was extracted and genotyping performed for GSTM1. Data were available for 279 cases and 340 controls. The null allele did not increase breast cancer risk, regardless of menopausal status. There were also no differences in associations between the polymorphism and risk among lower and higher consumers of dietary sources of antioxidants or smokers and nonsmokers. These results indicate that GSTM1 genetic polymorphisms are not associated with breast cancer risk, even in an environment low in antioxidant defenses.  (+info)

Tumour necrosis factor-alpha (TNF-alpha) in human endometrium and uterine secretion: an evaluation by immunohistochemistry, ELISA and semiquantitative RT-PCR. (3/1495)

Tumour necrosis factor-alpha (TNF-alpha is a pleiotropic cytokine synthesized throughout the female reproductive tract. Even though evidence has accumulated that supports its role in autocrine and paracrine processes, its expression and function in the human endometrium are still not completely understood. To gain a better understanding of the synthesis and release of TNF-alpha in the endometrium and how this relates to concentrations in uterine secretion, its expression throughout the menstrual cycle was investigated by three different techniques. Samples of endometrial tissue and uterine secretions were collected from patients undergoing abdominal and vaginal hysterectomy for benign reasons. The mRNA expression of TNF-alpha was investigated in homogenized endometrial tissue by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) (n = 18). An assessment of the cellular TNF-alpha protein localization in the endometrial glands was performed immunohistochemically (n = 39). The concentrations of the secreted TNF-alpha protein in endometrial secretion were determined by enzyme-linked immunosorbent analysis (n = 30). All three methods gave similar results on the temporal expression of TNF-alpha mRNA and TNF-alpha protein during the cycle. Concentrations of endometrial TNF-alpha mRNA in tissue samples and TNF-alpha protein in uterine secretion were quite low at the beginning of the cycle, rose sharply in the mid- to late proliferative phase and decreased towards the end of the cycle. The concentrations of TNF-alpha protein in the endometrial glands, as shown by immunohistochemical investigation, stayed high throughout the secretory phase at values slightly below those of the late proliferative phase.  (+info)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. (4/1495)

Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer, or with response to tamoxifen therapy in recurrent disease. PSA levels were determined by enzyme-linked immunosorbent assay (ELISA) in breast tumour cytosols, and were correlated with prognosis in 1516 patients with primary breast cancer and with response to first-line tamoxifen therapy in 434 patients with recurrent disease. Relating the levels of PSA with classical prognostic factors, low levels were more often found in larger tumours, tumours of older and post-menopausal patients, and in steroid hormone receptor-negative tumours. There was no significant association between the levels of PSA with grade of differentiation or the number of involved lymph nodes. In patients with primary breast cancer, PSA was not significantly related to the rate of relapse, and a positive association of PSA with an improved survival could be attributed to its relationship to age. In patients with recurrent breast cancer, a high level of PSA was significantly related to a poor response to tamoxifen therapy, and a short progression-free and overall survival after start of treatment for recurrent disease. In Cox multivariate analyses for response to therapy and for (progression-free) survival, corrected for age/menopausal status, disease-free interval, site of relapse and steroid hormone receptor status, PSA was an independent variable of poor prognosis. It is concluded that the level of PSA in cytosols of primary breast tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy.  (+info)

Menopausal status and distensibility of the common carotid artery. (5/1495)

Although several studies have shown that exogenous estrogens have beneficial effects on arterial characteristics, the effect of endogenous estrogen on the vascular system is still unknown. In this study, distensibility, an indicator of arterial elasticity, of the common carotid artery was compared in pre- and postmenopausal women. The study comprised 93 premenopausal and 93 postmenopausal women of similar age (range, 43 to 55 years). Women were selected from respondents to a mailed questionnaire about the menopause, which was sent to all women aged 40 to 60 years in the Dutch town of Zoetermeer (n=12 675). Postmenopausal women who were at least 3 years past natural menopause or whose menses had stopped naturally before age 48, were age-matched with premenopausal women with regular menses and without menopausal complaints. The selection aimed at maximizing the contrast in estrogen status between pre- and postmenopausal women of the same age. Distensibility of the carotid artery was measured noninvasively with B-mode ultrasound and a vessel wall movement detector system. Arterial distensibility is expressed as the change in arterial diameter (distension, DeltaD) with the cardiac cycle, adjusted for lumen diameter, pulse pressure, and mean arterial blood pressure. Compared with premenopausal women, postmenopausal women had significantly lower arterial distension (DeltaD 370.5 microm [SE 9.5] versus 397.3 microm [SE 9.6]). These results suggest that the distensibility of the common carotid artery is negatively affected by natural menopause in presumed healthy women.  (+info)

Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. (6/1495)

BACKGROUND: There is compelling evidence that estrogens influence breast cancer risk. Since the mid-1980s, dietary fat intervention studies have been conducted to investigate the effect of fat intake on endogenous estrogen levels. To further our understanding of the possible relationship between dietary fat and breast cancer, we conducted a meta-analysis of dietary fat intervention studies that investigated serum estradiol levels, and we reviewed the nature of the evidence provided by prospective analytic studies of fat consumption and breast cancer risk. METHODS: A computerized search of the English language literature on estrogen/estradiol and dietary fat intervention studies published from January 1966 through June 1998 was conducted using the MEDLINE database. Pooled estimates were derived from the change in estradiol levels associated with fat reduction from 13 studies. Analyses were conducted separately for premenopausal and postmenopausal women and in both groups combined. RESULTS AND CONCLUSIONS: Statistically significant reductions in serum estradiol levels of -7.4% (95% confidence interval [CI] = -11.7% to -2.9%) among premenopausal women and -23.0% (95% CI = -27.7% to -18.1%) among postmenopausal women were observed, with an overall -13.4% (95% CI = -16.6% to -10.1%) reduction observed. The greatest reductions occurred in two studies in which dietary fat was reduced to 10%-12% of calories compared with 18%-25% of calories in the other studies. A statistically significant reduction in estradiol levels of -6.6% (95% CI = -10.3% to -2.7%) remained after exclusion of these two studies. Review of prospective analytic epidemiologic studies that allowed for dietary measurement error suggests that the possibility that reducing fat consumption below 20% of calories will reduce breast cancer risk cannot be excluded. IMPLICATIONS: Dietary fat reduction can result in a lowering of serum estradiol levels and such dietary modification may still offer an approach to breast cancer prevention.  (+info)

Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. (7/1495)

BACKGROUND: Data on intake of specific carotenoids and breast cancer risk are limited. Furthermore, studies of vitamins A, C, and E in relation to breast cancer risk are inconclusive. We have conducted a large, prospective study to evaluate long-term intakes of these nutrients and breast cancer risk. METHODS: We examined, by use of multivariate analysis, associations between intakes of specific carotenoids, vitamins A, C, and E , consumption of fruits and vegetables, and breast cancer risk in a cohort of 83234 women (aged 33-60 years in 1980) who were participating in the Nurses' Health Study. Through 1994, we identified 2697 incident cases of invasive breast cancer (784 premenopausal and 1913 postmenopausal). RESULTS: Intakes of beta-carotene from food and supplements, lutein/zeaxanthin, and vitamin A from foods were weakly inversely associated with breast cancer risk in premenopausal women. Strong inverse associations were found for increasing quintiles of alpha-carotene, beta-carotene, lutein/zeaxanthin, total vitamin C from foods, and total vitamin A among premenopausal women with a positive family history of breast cancer. An inverse association was also found for increasing quintiles of beta-carotene among premenopausal women who consumed 15 g or more of alcohol per day. Premenopausal women who consumed five or more servings per day of fruits and vegetables had modestly lower risk of breast cancer than those who had less than two servings per day (relative risk [RR] = 0.77; 95% confidence interval [CI] = 0.58-1.02); this association was stronger among premenopausal women who had a positive family history of breast cancer (RR = 0.29; 95% CI = 0.13-0.62) or those who consumed 15 g or more of alcohol per day (RR = 0.53; 95% CI = 0.27-1.04). CONCLUSIONS: Consumption of fruits and vegetables high in specific carotenoids and vitamins may reduce premenopausal breast cancer risk.  (+info)

The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women. (8/1495)

OBJECTIVE: To determine whether Caucasian women ages 28-48 years with newly defined osteoarthritis (OA) would have greater bone mineral density (BMD) and less bone turnover over time than would women without OA. METHODS: Data were derived from the longitudinal Michigan Bone Health Study. Period prevalence and 3-year incidence of OA were based on radiographs of the dominant hand and both knees, scored with the Kellgren/Lawrence (K/L) scale. OA scores were related to BMD, which was measured by dual-energy x-ray absorptiometry, and to serum osteocalcin levels, which were measured by radioimmunoassay. RESULTS: The period prevalence of OA (K/L grade > or =2 in the knees or the dominant hand) was 15.3% (92 of 601), with 8.7% for the knees and 6.7% for the hand. The 3-year incidence of knee OA was 1.9% (9 of 482) and of hand OA was 3.3% (16 of 482). Women with incident knee OA had greater average BMD (z-scores 0.3-0.8 higher for the 3 BMD sites) than women without knee OA (P < 0.04 at the femoral neck). Women with incident knee OA had less change in their average BMD z-scores over the 3-year study period. Average BMD z-scores for women with prevalent knee OA were greater (0.4-0.7 higher) than for women without knee OA (P < 0.002 at all sites). There was no difference in average BMD z-scores or their change in women with and without hand OA. Average serum osteocalcin levels were lower in incident cases of hand OA (>60%; P = 0.02) or knee OA (20%; P not significant). The average change in absolute serum osteocalcin levels was not as great in women with incident hand OA or knee OA as in women without OA (P < 0.02 and P < 0.05, respectively). CONCLUSION: Women with radiographically defined knee OA have greater BMD than do women without knee OA and are less likely to lose that higher level of BMD. There was less bone turnover among women with hand OA and/or knee OA. These findings suggest that bone-forming cells might show a differential response in OA of the hand and knee, and may suggest a different pathogenesis of hand OA and knee OA.  (+info)

Causes of Premature Menopause:

1. Genetic factors: Women with a family history of premature menopause are more likely to experience it themselves.
2. Autoimmune disorders: Conditions such as thyroiditis, type 1 diabetes, and lupus can increase the risk of premature menopause.
3. Chemotherapy and radiation therapy: These cancer treatments can damage the ovaries and cause premature menopause.
4. Surgery: Removal of the ovaries or hysterectomy (removal of the uterus) can cause premature menopause.
5. Premature birth: Babies born prematurely are at a higher risk of developing premature menopause later in life.
6. Ovarian torsion: This is a rare condition where the ovary becomes twisted, cutting off blood flow and causing premature menopause.
7. Endometriosis: This condition can cause inflammation of the ovaries, leading to premature menopause.
8. Pelvic adhesions: Scar tissue in the pelvis can cause the ovaries to become damaged, leading to premature menopause.
9. Radiation exposure: Exposure to high levels of radiation, such as during a nuclear accident, can damage the ovaries and cause premature menopause.
10. Tobacco smoke: Exposure to secondhand smoke can increase the risk of premature menopause.

Symptoms of Premature Menopause:

1. Amenorrhea (absence of periods)
2. Infertility
3. Hot flashes and night sweats
4. Vaginal dryness and pain during sex
5. Mood changes, such as anxiety and depression
6. Sleep disturbances
7. Weight gain and fatigue
8. Memory problems and difficulty concentrating
9. Thinning hair and skin changes
10. Increased risk of osteoporosis and heart disease.

Diagnosis and Treatment:

1. Blood tests to check for hormone levels and follicle-stimulating hormone (FSH) levels.
2. Ultrasound to check for ovary size and egg quantity.
3. Hysterosalpingography (HSG) or laparoscopy to check for blockages in the reproductive tract.
4. Genetic testing to identify genetic mutations that may be causing premature menopause.
5. Hormone replacement therapy (HRT) to relieve symptoms and prevent bone loss.
6. Medications to treat hot flashes and sleep disturbances.
7. Lifestyle changes, such as avoiding smoking, alcohol, and caffeine, and exercising regularly.
8. Infertility treatment, such as in vitro fertilization (IVF), if desired.
9. Management of related health risks, such as osteoporosis and heart disease prevention.

Prognosis:
The prognosis for premature menopause is generally good, but it can be challenging to adjust to the changes that come with it. Women who experience premature menopause may need to make significant lifestyle changes to manage symptoms and prevent health risks. However, many women are able to lead fulfilling lives and have successful pregnancies with the help of medical treatment and lifestyle modifications.

Donnez, J. (2011). "Menometrorrhagia during the premenopause: An overview". Gynecological Endocrinology. 27: 1114-1119. doi: ... "Current and future medical treatments for menometrorrhagia during the premenopause". Gynecological Endocrinology. 27 ( ...
The medical management of menopause and premenopause: their endocrinologic basis. Lippincott Williams & Wilkins. p. 31. ISBN ...
Premenopause is a term used to mean the years leading up to the last period, when the levels of reproductive hormones are ... Premenopause starts some time before the monthly cycles become noticeably irregular in timing. The term "perimenopause", which ... During perimenopause, estrogen levels average about 20-30% higher than during premenopause, often with wide fluctuations. These ... Birkhaeuser M, Genazzani AR (30 January 2018). Pre-Menopause, Menopause and Beyond: Volume 5: Frontiers in Gynecological ...
All care after childbirth recovery is typically excluded, which includes pre-menopause and aging into old age. During ...
A lot of women also begin the pre-menopause stage at this time, and many men experience the 'male menopause'. Permanent and ...
This idea fit his observation that it more common for women in menopause and pre-menopause to develop breast lesions. Unlike ...
Estrogen produced pre-menopause has a dampening effect on dopamine receptors but its protection can be overridden by a genetic ...
... whereas the risk of this type of progression in premenopause females increases with an increase in the number of different ...
... premenopause MeSH G08.520.960.374 - puberty MeSH G08.520.960.374.204 - adrenarche MeSH G08.520.960.374.410 - menarche MeSH ...
Those in pre-menopause using progestin contraceptives have some compensation for the high levels of estradiol, though after ...
Went into pre-menopause and gained 40 lbs. Ive tried several diets, including the 6 week body makeover. I just dont know what ...
ClinicalTrials.gov: Premenopause (National Institutes of Health) Journal Articles References and abstracts from MEDLINE/PubMed ...
Premenopause. EN. dc.subject.mesh. Breast Neoplasms. EN. dc.title. Breast cancer in Egypt: a review of disease presentation and ...
Hormone imbalance causes premenopause symptoms or early signs of menopause. If you would like to avoid synthetic HRT (Hormone ...
My mom has excessive bleeding for 3 weeks every month with sometimes big baseball size clumps during pre menopause. what to do ...
Pre-menopause, or perimenopause, can start as early as the mid-30s, and its time we start talking about it. ...
In premenopause, your brain energy is.. Weston, but on your account. On no account would i lose sight of you. Com please ...
In addition, higher fasting blood measures, sugar intakes and poorer sleep were recorded in post-menopause versus pre-menopause ...
This would appear to indicate that EACH INDIVIDUAL DRINK increases the risk by 5% or 9%. Is this correct? Once a pre-menopause ...
During pre-menopause, many women endure symptoms including hot flashes, vaginal problems and bone loss as a result of the ...
People usually get confused between premenopause and perimenopause.. Premenopause is applicable to any woman in any phase of ... Therefore, a fertile woman is also part of the premenopause group. Perimenopause, on the other hand, are the handful of years ... The time period from when womens menstruation starts in the teenage, till it ends in menopause, is considered premenopause. ...
The Other Premenopause. *How Could Fasting Help Fight Cancer?. *Why Is Vitamin D So Important? ...
People with signs of osteoporosis (especially during premenopause and menopause) and those in the period of bone healing after ...
Perfect Pre-Menopause Training. Hosted by Bria Gadd, Holistic Health Coach, Female Hormone Specialist, Personal Trainer and ...
Pre Menopause Post Menopause. Menstruation is a periodic process where the body removes impurities from its system.... ...
22:17] Cassy Price: Earlier you mentioned that it can also be used postpartum and pre-menopause. What are the benefits after ...
Premenopause vs. Perimenopause: Whats the Difference? Menopause is a normal biological process that affects females at some ...
She will advise on the differences in the body pre-menopause and post-menopause and give the best advice on Nutrition and ...
PERIMENOPAUSE; PREMENOPAUSE; and POSTMENOPAUSE are available. Allowable Qualifiers:. BL blood. CF cerebrospinal fluid. DE drug ...
D4.210.500.745.745.725.703 Premenopause G8.686.785.880.249.500.812 G8.686.841.249.500.812 Prenatal Nutritional Physiological ...
Keywords: Menopause, post-menopause, somatic, pre-menopause. 4. Pollination efficiency of Apis mellifera (Hymenoptera: Apidae) ...
Hubungan antara Aktivitas Fisik dan Gejala Premenopause pada Perempuan Pascamenopause (2558 Downloads) ...
And if youre in premenopause or are experiencing signs of menopause, you can talk to your doctor about specific tests that ...
Premenopause? Can you repeat that?. So I cant eat anything I want anymore?? ...
Web Privacy. Links from websites affiliated with The University of Texas Health Science Center at San Antonios website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.. Copyright © 2023 UT Health San Antonio. ...
Pre-menopause: When no menopausal symptoms are noticeable. Peri-menopause: When symptoms begin to develop due to hormone ...
  • But before both the menopause and the perimenopause phases, the period where hormonal shifts begin is termed premenopause. (mycarmesi.com)
  • The final study analysis dataset covered 1,690 midlife women aged 42 to 52 years in premenopause (unchanged menstrual cycles) or early perimenopause. (news-medical.net)
  • The majority of women veterans require family planning resources, prenatal and maternity care, or premenopause and perimenopause care. (vfw.org)
  • Though the word is sometimes used to describe any menstruating phase in a woman's life before menopause, usually premenopause indicates the time when hormonal changes begin to occur. (mycarmesi.com)
  • Hormone imbalance causes premenopause symptoms or early signs of menopause. (safemenopausesolutions.com)
  • Community-based prospective longitudinal studies of women transitioning through menopause document that women are at increased risk for both new-onset and recurrent depression during the MT (i.e., perimenopausal depression PMD) compared with both premenopause and several years postmenopause. (nih.gov)
  • Are there any symptoms of premenopause? (mycarmesi.com)
  • Due to the lack of symptoms in most cases, it is harder to detect premenopause. (mycarmesi.com)
  • Usually, there are no outward symptoms of premenopause and thus treatment is not required. (mycarmesi.com)
  • But, the number starts to fall as a woman enters her premenopausal years and tests can be run to find out how many eggs are present to determine if she has entered premenopause. (mycarmesi.com)
  • Community-based prospective longitudinal studies of women transitioning through menopause document that women are at increased risk for both new-onset and recurrent depression during the MT (i.e., perimenopausal depression PMD) compared with both premenopause and several years postmenopause. (nih.gov)
  • The main findings were that 39.84% of included studies were consistent with STRAW classification of premenopause, whereas 70.31% were consistent with STRAW classification of postmenopause. (bvsalud.org)
  • The present findings indicate that there is a significant amount of heterogeneity associated with the definition of premenopause, compared with postmenopause. (bvsalud.org)
  • Surprisingly, major inconsistencies relating to premenopause definition were due to a total lack of reporting of any definitions/criteria for premenopause (39.84% of studies). (bvsalud.org)